This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glenn, G. M.
Right arrow Articles by Frech, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glenn, G. M.
Right arrow Articles by Frech, S. A.

 Previous Article  |  Next Article 

Infection and Immunity, May 2007, p. 2163-2170, Vol. 75, No. 5
0019-9567/07/$08.00+0     doi:10.1128/IAI.01740-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Safety and Immunogenicity of an Enterotoxigenic Escherichia coli Vaccine Patch Containing Heat-Labile Toxin: Use of Skin Pretreatment To Disrupt the Stratum Corneum{triangledown}

Gregory M. Glenn,1,2* Christina P. Villar,1 David C. Flyer,1 A. Louis Bourgeois,2 Robin McKenzie,2 Robert M. Lavker,3 and Sarah A. Frech1

IOMAI Corporation, 20 Firstfield Road, Gaithersburg, Maryland 20878,1 Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, 624 North Broadway, Baltimore, Maryland 21205,2 Northwestern University School of Medicine, Department of Dermatology, 303 East Chicago Avenue, Chicago, Illinois 606113

Received 31 October 2006/ Returned for modification 17 December 2006/ Accepted 21 January 2007

Transcutaneous immunization allows safe delivery of native heat-labile enterotoxin (LT) from Escherichia coli via application of a simple patch. Physical disruption of the stratum corneum can improve the efficiency of delivery. In the current study, the stratum corneum was disrupted using an electrocardiogram prep pad prior to patch application. The effects were quantified using transepidermal water loss (TEWL) and were correlated with the immune responses. Sixty adults received 50 µg of LT from three lots of LT (20 adults per group) administered in a patch on days 0 and 21. The immunizations were well tolerated. There were no differences in the anti-LT immunoglobulin G (IgG) titers between the three LT lots; the seroconversion rate was 100%, and the mean anti-LT IgG titer was 12,185 enzyme-linked immunosorbent assay units (EU) (a 24-fold increase). TEWL measurements obtained at the time of the second immunization were found to correlate with the day 42 individual increases in the anti-LT IgG titer (r = 0.59, P < 0.001). In a comparative assessment of the immune responses, sera after an LT+ ST+ (E2447A) oral ETEC challenge, which induced moderate to severe diarrhea in 81% of the recipients, had anti-LT IgG titers of 3,245 EU (a 10.8-fold increase). Similarly, the anti-LT IgG titer after administration of an oral cholera toxin B subunit-containing cholera vaccine, which cross-reacts with LT and protects against LT and LT/heat-stable toxin ETEC disease in the field, was 6,741 EU (a 3.3-fold increase). This study confirmed that a well-tolerated regimen for stratum corneum disruption before vaccine patch application results in robust immunity comparable to natural immunity and vaccine-induced immunity and that the magnitude of stratum corneum disruption correlates with the immune response.


* Corresponding author. Mailing address: IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878. Phone: (301) 556-4539. Fax: (301) 556-4501. E-mail: gglenn{at}iomai.com

{triangledown} Published ahead of print on 29 January 2007.

Editor: A. Camilli


Infection and Immunity, May 2007, p. 2163-2170, Vol. 75, No. 5
0019-9567/07/$08.00+0     doi:10.1128/IAI.01740-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.